Treatments-related cardiotoxicity is a critical issue in long term lymphoma survivors, particularly at young age, and its early identification is important to prevent clinically relevant cardiac events. Complete echocardiographic assessment including 2-dimension global longitudinal strain (2D-GLS), seems to be an effective tools in detecting preclinical systolic changes to the cardiac function even when the ejection fraction is preserved. The aim of Cardiocare study is to investigate early detection of subclinical chemo and radiation-induced changes in left ventricular function using 2D-GLS.

Inclusion Criteria:

• Age >18 years
• Diagnosis of Hodgkin Disease (HD) or Primary Mediastinal B-cell lymphoma (PMBCL) or diffuse large B-cell lymphoma (DLBCL)
• Disease requiring treatment with anthracycline containing regimen only (cohort A) or anthracycline containing regimen followed by mediastinal radiotherapy (cohort B)
• Written informed consent

Exclusion Criteria:

• Age > 70 years
• Unable to perform anthracyline containing regimen
• Previous treatment with mediastinal radiotherapy
• Kidney failure (defined as creatinine x2 UNL) or liver failure (defined as AST and ALT x2 UNL)
• ECOG PS > 2
• Echocardiographic acoustic windows not suitable for strain evaluation
• Any other conditions or situations preventing patients to sign informed consent

Patient 19-70 years old with HD or PMBCL or DLBCL requiring treatment with chemotherapy or chemotherapy plus mediastinal radiotherapy suitable for a strain-rate echocardiograpy evaluation